AXSM Latest Press Releases

-- October 7, 2026 --

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 Globe Newswire 7:00 AM

-- September 21, 2026 --

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day Globe Newswire 7:00 AM

-- September 17, 2026 --

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 Globe Newswire 7:00 AM

-- September 2, 2026 --

Axsome Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 31, 2026 --

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation Globe Newswire 7:00 AM

-- August 10, 2026 --

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- July 15, 2026 --

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy Globe Newswire 7:00 AM

-- July 14, 2026 --

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 Globe Newswire 7:00 AM

-- July 7, 2026 --

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) Globe Newswire 7:00 AM

-- June 26, 2026 --

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) Globe Newswire 7:00 AM

-- June 18, 2026 --

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month Globe Newswire 7:00 AM

-- June 15, 2026 --

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 Globe Newswire 7:00 AM

-- June 4, 2026 --

Axsome Therapeutics Presents New SYMBRAVO Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting Globe Newswire 7:00 AM

-- June 3, 2026 --

Axsome Therapeutics Announces Settlement Resolving All SUNOSI (solriamfetol) Patent Litigation Globe Newswire 7:00 AM

-- June 1, 2026 --

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month Globe Newswire 7:00 AM

-- May 27, 2026 --

Axsome Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- May 26, 2026 --

Axsome Therapeutics Presents New AUVELITY Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes